RSV+HMPV vaccine

Preclinical

RSV+HMPV vaccine is one of 2 therapeutic programs targeting Respiratory Syncytial Virus Immunization. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Respiratory Syncytial Virus ImmunizationRecruiting

Respiratory Syncytial Virus ImmunizationPreclinical

Recruiting

Competition

Competitive Landscape

1 competitor in Respiratory Syncytial Virus Immunization

#DrugCompanyPhaseTrials

Control Vaccine

GSK

Preclinical

1 2

RSV+HMPV vaccine

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

PreclinicalRecruiting

Respiratory Syncytial Virus Immunization

NCT07734649

Clinical

Trials by Indication[1]

Respiratory Syncytial Virus Immunization1 trial

A Phase 1/2, Randomized, Controlled, Observer-Blind Study in Adults 60 Years of Age and Older to Evaluate the Immunogenicity and Safety of Different Dose Levels of a Bivalent Vaccine Candidate Against Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMPV)

Recruiting· Sanofi logo

Sanofi·Preclinical·NCT07734649·2,400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RSV+HMPV vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for RSV+HMPV vaccine. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: Sanofi

RSV+HMPV vaccine

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Respiratory Syncytial Virus Immunization1 trial

References

Drug Info

Quick Facts

Related News